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anemic patients. Comparisons were adjusted for patient gender,
insurance coverage type, predisposing condition, and disease
severity for each predisposing condition using ordinary least
squares regression of log-transformed costs. RESULTS: Utiliza-
tion and costs were signiﬁcantly higher for anemic patients (p <
0.0001). Average annualized per patient costs were $14,535 
for anemic patients (55% outpatient; 33% inpatient) compared
to $9451 for non-anemic patients (45% outpatient; 36% inpa-
tient). Outpatient pharmacy costs averaged $1833 for anemic
patients and $1813 for non-anemic patients (p = 0.24). Signiﬁ-
cant differences persisted after adjusting for covariates. 
CONCLUSIONS: Medical costs of anemic patients are as much
as twice those of non-anemic patients after adjusting for several
potential confounders. These results suggest that anemia may be
responsible for signiﬁcant excess health care costs, though resid-
ual confounding may account for some of the observed differ-
ences. A large-scale treatment trial would be required to establish
deﬁnitively the causal role of anemia and anemia treatment in
health care utilization/costs and in medical outcomes.
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OBJECTIVE: To obtain patient perspectives on (1) factors
important in SCD-related HrQoL and (2) current impediments
to QoL. METHODS: Four semi-structured focus groups were
conducted with African American sickle cell disease (SCD)
patients, 21–26 years old. Subjects were recruited from a tertiary
care academic center or a community setting. Inductive analysis
of verbatim transcripts assisted with computer software resulted
in over 200 codes grouped into ﬁve themes: illness experience,
health care system, social networks, life stages/transition, and
community/society. RESULTS: Young adults with SCD faced
similar issues as those with other chronic health conditions:
greater responsibility associated with autonomy and difﬁculty
developing relationships with unfamiliar providers. Patients also
faced challenges unique to SCD. The unpredictability of SCD
and its associated multi-organ system complications implies
recurrent illness and pain episodes, requiring a greater focus on
acute medical events rather than on chronic health maintenance.
Furthermore, SCD heterogeneity, both between patients and
within each individual, resulted in difﬁculty predicting disease
course, limiting the attainment of occupational and educational
goals. Patient autonomy was often undermined by a need to rely
on social support systems during acute illness. Patients con-
tended with health care provider misperceptions, e.g., underesti-
mation of their pain severity based upon outward appearance;
being labeled as “drug-seeking” when notifying providers of 
successful pain strategies. Patient frustration with lack of access
to SCD specialists in the community setting was confounded by
a lack of public awareness of SCD-related issues. Informants also
described economic challenges and faced limitations imposed by
reliance on governmental assistance, such as fewer providers,
limited coverage, loss of beneﬁts with employment and difﬁculty
obtaining health insurance due to preexisting illness. CON-
CLUSIONS: The impact of SCD far exceeds the clinical mani-
festations of the illness. Patients are faced with life interruptions,
social limitations, and physical challenges that impede function-
ing in an uninhibited society.
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OBJECTIVES: Due to an ongoing increase in demand for blood
transfusions alongside a decline in blood donation and concern
about the safety of donated blood, there is a crisis in blood dona-
tion. This study therefore aims to evaluate different motivators
for blood donation focusing on the potential of incentives to
increase donation, whilst maintaining blood safety. METHODS:
A literature review was carried out. Medline, Embase and Psych-
info databases were searched and studies about autologous and








were excluded. RESULTS: The included studies were varied in
focus, study design and conclusions. They researched the impact
of different types of incentives examining their ability to attract
donors and maintain blood safety by preventing disease trans-
mission. Commonly mentioned incentives were free medical
tests, blood credits, paid time off and tickets to events, such as
concerts. The success of incentives to attract donors is dependent
upon age with younger donors being more receptive to most
incentives than older donors. However, offering free cholesterol
and PSA screening also motivates older donors. Using these types
of medical tests as incentives is unlikely to detrimentally affect
blood safety. However, there is considerable debate concerning
the use of incentives with monetary value. There are data
showing that the safety of donated blood is not adversely
affected by such incentives, but there are also data showing a
high response to such incentives by high-risk donors who donate
in order to receive HIV testing. CONCLUSIONS: The positive
impact of incentives with monetary value is limited by their
appeal to donors from high-risk groups. However, if blood incen-
tive programmes are organised at regional or communal levels
as opposed to national levels it may be possible to take advan-
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OBJECTIVES: To evaluate the clinical signiﬁcance of a greater
area under the hemoglobin change curve (Hb AUC) value during
epoetin alfa (EPO) treatment. METHODS: Datasets from two
EPO trials were used (Study 1: N = 2964; Study 2: N = 2289).
Initial EPO regimens were: Study 1: 40,000IU once weekly
(QW), Study 2: 10,000IU thrice weekly (TIW). Each study
allowed for potential dose escalation to 60,000IU QW and
20,000IU TIW respectively. Patients were *0.35618 years, had
a baseline Hb of £11g/dL, and received concomitant chemother-
apy. Outcome measures included: blood transfusions, quality of
life (QoL) measured by Linear Analog Scale Assessment and
Functional Assessment of Cancer Therapy Anemia and Fatigue,
drug utilization and hematopoietic response. All missing values
were imputed based on a last-value-carried-forward principle.
Hb AUC values (g/dL) from baseline to 16 weeks were stratiﬁed
into ﬁve groups established based on data frequency distribu-
tions and clinical judgment (Hb AUC 1: <11; Hb AUC 2: 11 –
< 18; Hb AUC 3: 18 – < 25; Hb AUC 4: 25 – < 32; Hb AUC 5:
> 32). RESULTS: Mean Hb AUCs were similar (Study 1: 19.7
g/dL, Study 2: 21.3g/dL). For Hb AUC groups 1–5 respectively,
the following signiﬁcant trends were observed for patients with
greater Hb AUC values: decreased transfusion use (%) (Study 1:
41, 24, 15, 14, 10; Study 2: 46, 33, 24, 21, 15), increased QoL
across all domains, reduced weekly dose (IU) (Study 1: 45,934,
45,130, 42,596, 41,021, 39,478; Study 2: 38,643, 37,752,
35,011, 33,853, 31,459) and improved hematopoietic response
(%) (Study 1: 13, 54, 85, 98, 100; Study 2: 8, 52, 79, 96, 100).
CONCLUSIONS: Hb AUC is a comprehensive efﬁcacy measure
reﬂecting Hb change over the entire treatment course. Greater
Hb AUC values are associated with a reduction in transfusion
requirements, improved QoL and drug utilization outcomes,
conﬁrming its clinical signiﬁcance.
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OBJECTIVE: To formulate a more comprehensive and general-
izable model than is currently available that fully accounts for
costs associated with blood transfusions. METHODS: A con-
sensus panel of experts in transfusion medicine was organized
by the Society for the Advancement of Blood Management
(SABM), representing clinical, blood banking, and academic
interests. An iterative process was used to reﬁne data from work-
sheets that had been distributed, collected, and summarized prior
to the conference. RESULTS: A detailed process-ﬂow model was
constructed, encompassing both direct and indirect cost ele-
ments. Major steps and critical interdependencies were identi-
ﬁed, including donor recruitment/qualiﬁcation, blood collection,
blood component processing, laboratory testing, unit tracking
and labeling, blood destruction, donor notiﬁcation and tracking,
blood center/collection facility inventory, storage, and transport,
transfusion service inventory and storage, pretransfusion prepa-
ration, transfusion administration and follow-up, and long-term
outcomes tracking. Within these major steps, 248 cost elements
were itemized. The relative importance and degree of difﬁculty
associated with collecting cost data for each element were rated.
Panelists rated personnel, screening for infectious agents, infor-
mation systems, laboratory evaluations, transfusion reaction
management, and equipment as the most important elements to
capture. Limitations in current process-ﬂow models were recog-
nized, with deﬁciencies in accounting for both direct and indi-
rect costs. Work is in progress to convert the present model into
one that employs activity-based costing (ABC) which will correct
the underestimates of blood costs provided in existing literature.
CONCLUSIONS: Accounting for the cost of blood is an enor-
mously complex undertaking and a standard, widely applicable
methodology is needed. As presented, this process-ﬂow diagram
and comprehensive set of cost elements should be of interest to
providers, payers, and society. When completed, the ABC model
will be a more precise means to compare the cost of blood to
that of transfusion alternatives or for evaluating safety-related
improvements to blood administration technology.
